
    
      HER2 negative advanced gastric cancer patients who have disease progression after two
      standard regimens will be treated by metronomic capecitabine plus camrelizumab. Metronomic
      capecitabine will be given as fixed dose (500mg bid) orally. Camrelizumab will be given
      two-weekly (200mg once) intravenously. This regimen will be administered until progression of
      disease, intolerable toxicity or withdraw of consent.
    
  